Which sulfonylurea is most appropriate in a patient with chronic kidney disease (eGFR ~50 mL/min) on metformin?

Which sulfonylurea is most appropriate in a patient with chronic kidney disease (eGFR ~50 mL/min) on metformin?

• A. Glyburide (Glibenclamide)
• B. Tolbutamide
• C. Glipizide
• D. Gliclazide

Answer: (B)

In kidney disease, how a drug is cleared and how long its effect lasts matter for safety. When kidney function is moderately reduced (eGFR around 50), you want a sulfonylurea that won’t tend to accumulate and cause prolonged hypoglycemia. Tolbutamide is a first‑generation sulfonylurea that is primarily processed by the liver and has a relatively short duration of action compared with some others. This makes it less likely to accumulate in moderate CKD and less likely to cause prolonged hypoglycemia if glucose falls, compared with agents that have active metabolites or longer half-lives. Glyburide (glibenclamide) is avoided in CKD because its active metabolites build up when the kidneys aren’t clearing well, increasing hypoglycemia risk. Glipizide and gliclazide are also liver‑metabolized and generally considered safer in CKD, but among the given options tolbutamide aligns with the goal of minimizing renal accumulation at an eGFR ~50. So, the choice reflects aiming to reduce drug accumulation and hypoglycemia risk in CKD by selecting a sulfonylurea with favorable pharmacokinetics in this setting. Monitor for hypoglycemia and adjust as needed when adding to metformin.

In kidney disease, how a drug is cleared and how long its effect lasts matter for safety. When kidney function is moderately reduced (eGFR around 50), you want a sulfonylurea that won’t tend to accumulate and cause prolonged hypoglycemia.

Tolbutamide is a first‑generation sulfonylurea that is primarily processed by the liver and has a relatively short duration of action compared with some others. This makes it less likely to accumulate in moderate CKD and less likely to cause prolonged hypoglycemia if glucose falls, compared with agents that have active metabolites or longer half-lives. Glyburide (glibenclamide) is avoided in CKD because its active metabolites build up when the kidneys aren’t clearing well, increasing hypoglycemia risk. Glipizide and gliclazide are also liver‑metabolized and generally considered safer in CKD, but among the given options tolbutamide aligns with the goal of minimizing renal accumulation at an eGFR ~50.

So, the choice reflects aiming to reduce drug accumulation and hypoglycemia risk in CKD by selecting a sulfonylurea with favorable pharmacokinetics in this setting. Monitor for hypoglycemia and adjust as needed when adding to metformin.